Prostate Cancer Diagnostics Market Size, Share & Trends Analysis Report By Test Type (Preliminary, Confirmatory (PCA3, Trans-rectal Ultrasound, Biopsy)), By Region, And Segment Forecasts, 2020 - 2027

Prostate Cancer Diagnostics Market Size, Share & Trends Analysis Report By Test Type (Preliminary, Confirmatory (PCA3, Trans-rectal Ultrasound, Biopsy)), By Region, And Segment Forecasts, 2020 - 2027

The global prostate cancer diagnostics market size is expected to reach USD 7.65 billion by 2027, registering a CAGR of 13.2% during the forecast period, according to a new report by Grand View Research, Inc. Major drivers include increasing government initiatives, high prevalence of prostate cancer, and technological advancements in confirmatory diagnostic tests.

High prevalence of the disease across the world is anticipated to be one of the major factors propelling the growth. According to the American Cancer Society, approximately one in nine men will be diagnosed with prostate cancer during the lifetime. It also states that the disease is the second most common form of cancer in U.S. after skin melanoma with over 174,650 new cases diagnosed in 2019.

Rise in government initiatives to enhance research associated with effective diagnosis and treatment is expected to boost growth of the market during the forecast period. For instance, the National Cancer Institute (NCI) initiated the study Research on Prostate Cancer in Men of African Ancestry: Defining the Roles of Genetics, Tumor Markers, and Social Stress (RESPOND). It is the largest collaboration to study the non-biological and biological factors associated with the disease among African American men. The initiative was launched by the NCI, National Institute on Minority Health, and Health Disparities in collaboration with Prostate Cancer Foundation; with a funding of USD 26 million.

Researchers from the University of Norfolk and East Anglia have developed a non-invasive urine test-the PUR test-for the diagnosis of aggressive prostate cancer. This test is performed on samples collected at home thereby preventing uncomfortable rectal examination. Additionally, researchers at Karolinska and KTH Institute concluded that the use of Artificial Intelligence (AI) in spatial transcriptomics can aid in the early detection, thereby, improving clinical diagnosis and treatment. Thus, such advancements are anticipated to positively impact the market growth in near future.

Approval of new diagnostic tests are expected to further boost market growth. For instance, in 2019, Bio Techne announced the approval from the New York State Department of Health for a liquid biopsy based test named ExoDx Prostate IntelliScore. The test assists clinicians to determine the need for biopsy with ambiguous PSA test result. Thus, rising disease prevalence coupled with technological advancements are the factors anticipated to fuel the market growth during the forecast period.

Further key findings from the report suggest:

  • PSA test is increasingly being used to detect prostate cancer among men that showcase no typical symptoms of the disease thereby facilitating the segment growth
  • Biomarker tests include Prostate Health Index (PHI) and 4Kscore, predict the probability of a patient developing prostate cancer and are anticipated to garner significant market share over the forecast period
  • Technological advancements in the healthcare sector and increasing prevalence of the disease contributed significantly toward growth of the North America market
  • Some of the major players in the prostate cancer diagnostics market include MDxHealth; 3D Signatures; Genomic Health; Abbott; OPKO Health, Inc.; Siemens Healthineers; bioMérieux SA; and F. Hoffman La Roche Ltd
Please note The report will be updated with the latest data and delivered to you within 2-3 business days.


Table of Contents Chapter 1 Methodology and Scope 1.1 Market segmentation & scope 1.2 Market definition 1.3 Information procurement 1.3.1 Purchased Database 1.3.2 Gvr’s Internal Database 1.3.3 Secondary Sources & Third Party Perspectives 1.3.4 Primary Research 1.4 Information analysis 1.4.1 Data Analysis Models 1.5 Market formulation & data visualization 1.6 Data validation & publishing Chapter 2 Executive Summary 2.1 Market Outlook 2.2 Segment Outlook 2.3 Competitive Insights Chapter 3 Prostate Cancer Diagnostics Market Variables, Trends & Scope 3.1 Market Lineage Outlook 3.1.1 Parent Market Outlook 3.1.2 Ancillary Market Outlook 3.2 Penetration And Growth Prospect Mapping 3.2.1 User Perspective Analysis 3.2.1.1 Consumer Behavior Analysis 3.3 Regulatory Framework 3.3.1 Reimbursement Framework 3.3.2 Standards And Compliances 3.4 Market Dynamics 3.4.1 Market Driver Analysis 3.4.1.1 Increasing Prevalence Of Prostate Cancer 3.4.1.2 Increasing Government Initiatives 3.4.1.3 Technological Advancements 3.4.2 Market Restraint Analysis 3.4.2.1 High Cost Of Diagnosis 3.4.3 Market Opportunities Analysis 3.4.4 Market Challenges Analysis 3.5 Prostate Cancer Diagnostics Market Analysis Tools 3.5.1 Industry Analysis - Porter’s 3.5.1.1 Supplier Power 3.5.1.2 Buyer Power 3.5.1.3 Substitution Threat 3.5.1.4 Threat from new entrants 3.5.1.5 Competitive Rivalry 3.5.2 Pestel Analysis 3.5.2.1 Political Landscape 3.5.2.2 Environmental Landscape 3.5.2.3 Social landscape 3.5.2.4 Services landscape 3.5.2.5 Legal Landscape 3.5.3 Major Deals And Strategic Alliances Analysis 3.5.3.1 Joint ventures 3.5.3.2 Mergers and acquisitions 3.5.3.3 Licensing and partnership 3.5.3.4 Services collaborations 3.5.3.5 Strategic Divestments Chapter 4 Prostate Cancer Diagnostics Market - Competitive Analysis 4.1 Recent Developments & Impact Analysis, by Key Market Participants 4.2 Company Categorization 4.2.1 List Of Key Distributors And Channel Partners 4.2.2 Key Company Market Share Analysis, 2019 4.3 Public Companies 4.3.1 Company Market Position Analysis 4.4 Private Companies 4.4.1 List Of Key Emerging Companies 4.4.2 Regional Network Map 4.4.3 Company Market Position Analysis Chapter 5 Prostate Cancer Diagnostics Market: Test Type Estimates and Trend Analysis 5.1 Definition & Scope 5.2 Test Type Market Share Analysis, 2019 & 2027 5.3 Segment Dashboard 5.4 Global Prostate Cancer Diagnostics Market, by Test Type, 2016 to 2027 5.5 Market Size & Forecasts and Trend Analyses, 2016 to 2027 5.6 Preliminary Tests 5.6.1 Preliminary Tests Market, 2016 To 2027 (USD Million) 5.7 Confirmatory Tests 5.7.1 Confirmatory Tests Market, 2016 To 2027 (USD Million) 5.7.1.1 Pca3 Test 5.7.1.1.1 Pca3 Test Market Size & Forecasts, 2016 To 2027 (USD Million) 5.7.1.2 Trans-Rectal Ultrasound 5.7.1.2.1 Trans-Rectal Ultrasound Market Size & Forecasts, 2016 To 2027 (USD Million) 5.7.1.3 Biopsy 5.7.1.3.1 Biopsy Market Size & Forecasts, 2016 To 2027 (USD Million) Chapter 6 Prostate Cancer Diagnostics Market: Regional Estimates & Trend Analysis 6.1 Regional Market Snapshot 6.2 Market Share Analysis by Country, 2019 6.2.1 North America 6.2.1.1 U.S. 6.2.1.2 Canada 6.2.2 Europe 6.2.2.1 U.K. 6.2.2.2 Germany 6.2.2.3 Spain 6.2.2.4 France 6.2.2.5 Italy 6.2.2.6 Russia 6.2.3 Latin America 6.2.3.1 Brazil 6.2.3.2 Mexico 6.2.3.3 Argentina 6.2.4 Asia Pacific 6.2.4.1 Japan 6.2.4.2 China 6.2.4.3 India 6.2.4.4 South Korea 6.2.4.5 Australia 6.2.4.6 Singapore 6.2.5 Middle East & Africa 6.2.5.1 South Africa 6.2.5.2 Saudi Arabia 6.2.5.3 Uae 6.3 Swot Analysis, By Factor (Political & Legal, Economic And Technological) 6.3.1 North America 6.3.2 Europe 6.3.3 Latin America 6.3.4 Asia Pacific 6.3.5 Middle East & Africa 6.4 Market Size & Forecasts, and Trend Analysis, 2016 to 2027 6.4.1 North America 6.4.1.1 Market Size, & Forecasts And Trend Analysis, 2016 To 2027 (USD Million) 6.4.1.2 U.S. 6.4.1.2.1 Market Size & Forecasts And Trend Analysis, By Test Type, 2016 To 2027 (USD Million) 6.4.1.3 Canada 6.4.1.3.1 Market Size & Forecasts And Trend Analysis, By Test Type, 2016 To 2027 (USD Million) 6.4.2 Europe 6.4.2.1 Market Size, & Forecasts And Trend Analysis, 2016 To 2027 (USD Million) 6.4.2.2 U.K. 6.4.2.2.1 Market Size & Forecasts And Trend Analysis, By Test Type, 2016 To 2027 (USD Million) 6.4.2.3 Germany 6.4.2.3.1 Market Size & Forecasts And Trend Analysis, By Test Type, 2016 To 2027 (USD Million) 6.4.2.4 France 6.4.2.4.1 Market Size & Forecasts And Trend Analysis, By Test Type, 2016 To 2027 (USD Million) 6.4.2.5 Italy 6.4.2.5.1 Market Size & Forecasts And Trend Analysis, By Test Type, 2016 To 2027 (USD Million) 6.4.2.6 Spain 6.4.2.6.1 Market Size & Forecasts And Trend Analysis, By Test Type, 2016 To 2027 (USD Million) 6.4.2.7 Russia 6.4.2.7.1 Market Size & Forecasts And Trend Analysis, By Test Type, 2016 To 2027 (USD Million) 6.4.3 Asia Pacific 6.4.3.1 Market Size, & Forecasts And Trend Analysis, 2016 To 2027 (USD Million) 6.4.3.2 Japan 6.4.3.2.1 Market Size & Forecasts And Trend Analysis, By Test Type, 2016 To 2027 (USD Million) 6.4.3.3 China 6.4.3.3.1 Market Size & Forecasts And Trend Analysis, By Test Type, 2016 To 2027 (USD Million) 6.4.3.4 India 6.4.3.4.1 Market Size & Forecasts And Trend Analysis, By Test Type, 2016 To 2027 (USD Million) 6.4.3.5 South Korea 6.4.3.5.1 Market Size & Forecasts And Trend Analysis, By Test Type, 2016 To 2027 (USD Million) 6.4.3.6 Australia 6.4.3.6.1 Market Size & Forecasts And Trend Analysis, By Test Type, 2016 To 2027 (USD Million) 6.4.3.7 Singapore 6.4.3.7.1 Market Size & Forecasts And Trend Analysis, By Test Type, 2016 To 2027 (USD Million) 6.4.4 Latin America 6.4.4.1 Market Size, & Forecasts And Trend Analysis, 2016 To 2027 (USD Million) 6.4.4.2 Brazil 6.4.4.2.1 Market Size & Forecasts And Trend Analysis, By Test Type, 2016 To 2027 (USD Million) 6.4.4.3 Mexico 6.4.4.3.1 Market Size & Forecasts And Trend Analysis, By Test Type, 2016 To 2027 (USD Million) 6.4.4.4 Argentina 6.4.4.4.1 Market Size & Forecasts And Trend Analysis, By Test Type, 2016 To 2027 (USD Million) 6.4.5 Middle East & Africa 6.4.5.1 Market Size, & Forecasts And Trend Analysis, 2016 To 2027 (USD Million) 6.4.5.2 South Africa 6.4.5.2.1 Market Size & Forecasts And Trend Analysis, By Test Type, 2016 To 2027 (USD Million) 6.4.5.3 Saudi Arabia 6.4.5.3.1 Market Size & Forecasts and Trend Analysis, By Test Type, 2016 to 2027 (USD Million) 6.4.5.4 UAE 6.4.5.4.1 Market Size & Forecasts and Trend Analysis, By Test Type, 2016 to 2027 (USD Million) Chapter 7 Company Profiles 7.1 Company Profiles 7.1.1 MDXHEALTH 7.1.1.1 Company overview 7.1.1.2 Financial Performance 7.1.1.3 Product benchmarking 7.1.1.4 Strategic initiatives 7.1.2 3D SIGNATURES 7.1.2.1 Company overview 7.1.2.2 Financial Performance 7.1.2.3 Product benchmarking 7.1.2.4 Strategic initiatives 7.1.3 GENOMIC HEALTH 7.1.3.1 Company overview 7.1.3.2 Financial Performance 7.1.3.3 Product benchmarking 7.1.3.4 Strategic initiatives 7.1.4 ABBOTT 7.1.4.1 Company overview 7.1.4.2 Financial Performance 7.1.4.3 Product benchmarking 7.1.4.4 Strategic initiatives 7.1.5 OPKO HEALTH, INC. 7.1.5.1 Company overview 7.1.5.2 Financial Performance 7.1.5.3 Product benchmarking 7.1.5.4 Strategic initiatives 7.1.6 SIEMENS HEALTHCARE GMBH 7.1.6.1 Company overview 7.1.6.2 Financial Performance 7.1.6.3 Product benchmarking 7.1.6.4 Strategic initiatives 7.1.7 DIASORIN S.P.A. 7.1.7.1 Company overview 7.1.7.2 Financial Performance 7.1.7.3 Product benchmarking 7.1.7.4 Strategic initiatives 7.1.8 BIOMÉRIEUX SA 7.1.8.1 Company overview 7.1.8.2 Financial Performance 7.1.8.3 Product benchmarking 7.1.8.4 Strategic initiatives 7.1.9 F. HOFFMAN LA ROCHE LTD. 7.1.9.1 Company overview 7.1.9.2 Financial Performance 7.1.9.3 Product benchmarking 7.1.9.4 Strategic initiatives 7.1.10 BECKMAN COULTER, INC. 7.1.10.1 Company overview 7.1.10.2 Financial Performance 7.1.10.3 Product benchmarking 7.1.10.4 Strategic initiatives 7.1.11 MYRIAD GENETIC, INC. 7.1.11.1 Company overview 7.1.11.2 Financial Performance 7.1.11.3 Product benchmarking 7.1.11.4 Strategic initiatives

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook